M. Zheng

发表

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial

G. Hortobagyi, W. Gradishar, S. Dakhil, 2017, JAMA oncology.

Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.

Jun-ping Wen, M. Zheng, Rong-fang Pan, 2013, World journal of gastroenterology.

Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine‐based chemotherapy: Evidence from 24 studies

X. Qian, J. Bai, M. Zheng, 2008, International journal of cancer.

P107 Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications

L. Rosen, Y. Hei, M. Zheng, 2005 .

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications.

L. Rosen, Y. Hei, V. Hirsh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer.

F. Saad, J. Chin, L. Lacombe, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases

A. Howell, A. Belch, L. Rosen, 2005 .

Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications.

L. Rosen, Y. Hei, M. Zheng, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Upregulation of vascular endothelial growth factor by hydrogen peroxide in human colon cancer.

Jianwei Zhu, M. Zheng, Dong-hua Li, 2002, World journal of gastroenterology.

615 Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases

F. Saad, J. Chin, L. Lacombe, 2004 .

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer-Reply.

G. Hortobagyi, M. Zheng, 2017, JAMA Oncology.

Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases

P. Conte, R. Dewar, A. Lipton, 2004 .

Expanding Nilotinib Access in Clinical Trials (ENACT)

Zhi-xiang Shen, F. Nicolini, N. Gallagher, 2012, Cancer.

Nilotinib ( formerly AMN 107 ) , a highly selective BCR-ABL tyrosine kinase inhibitor , is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia

J. Radich, R. Larson, M. Gobbi, 2008 .

Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.

W. Gradishar, H. Chew, C. V. Van Poznak, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

M. Krzakowski, L. Rosen, P. de Souza, 2004, Cancer.

Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.

P. Hegde, A. Jubb, H. Koeppen, 2010 .

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

F. Saad, J. Chin, L. Lacombe, 2004, Journal of the National Cancer Institute.

Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis

R. Cook, P. Major, M. Zheng, 2004 .

Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.

G. Hortobagyi, R. Mohanlal, M. Zheng, 2018, The oncologist.

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

F. Saad, Y. Hei, Janet E Brown, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

F. Saad, Y. Hei, Janet E Brown, 2005, Journal of the National Cancer Institute.

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

F. Saad, C. Higano, E. Small, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

J. Radich, R. Larson, M. Gobbi, 2008, Blood.

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

M. Krzakowski, L. Rosen, P. de Souza, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N. Chen, M. Zheng, L. Cui, 2018, European Archives of Oto-Rhino-Laryngology.

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

R. Larson, D. Marin, H. Kantarjian, 2010 .

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.

L. Rosen, Y. Hei, V. Hirsh, 2004, Clinical lung cancer.

The E-cadherin (CDH1) −160 C/A polymorphism and prostate cancer risk: a meta-analysis

W. Zhong, X. Qian, J. Bai, 2009, European Journal of Human Genetics.

Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid

R. Bukowski, L. Rosen, A. Lipton, 2004, Clinical Cancer Research.

Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma

A. Lipton, M. Zheng, J. Seaman, 2003, Cancer.

Sentinel lymph node and skip metastases in gastric cancer: a prospective study.

M. Zheng, Z. Su, Kuanshan Shu, 2013, Hepato-gastroenterology.

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

T. Masszi, F. Nicolini, N. Gallagher, 2012, Leukemia & lymphoma.

Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis.

R. Cook, P. Major, M. Zheng, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib

K. Bhalla, H. Kantarjian, F. Giles, 2007 .

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.

K. Bhalla, H. Kantarjian, G. Rosti, 2006 .

Plasma Kinetic Resection of Prostate Combined Terazosin for Treatment of BPH Patient with Coexisting Hypertension

M. Zheng, Chonghe Jiang, Ming-qiang Zeng, 2014 .

Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer; analysis by baseline pain

J. Eastham, F. Saad, J. McKiernan, 2005 .

Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.

W. Gradishar, H. Chew, C. V. Van Poznak, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors.

R. Cook, P. Major, M. Zheng, 2005, Supportive cancer therapy.